Navigation Links
InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
Date:5/4/2010

=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='92799664';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.intermune.com">www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 1-800-642-1687 (U.S.) or 1-706-645-9291 (international), and entering the conference ID# 73229257.  

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, which reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated regulatory timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company has submitted in support of its NDA and MAA filings. Other factors that could cause or contribute to such differences include, but are not limited
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 29
2. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
3. InterMune Announces Proposed Public Offering of Common Stock
4. InterMune to Release Third Quarter Financial Results on November 5
5. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
8. InterMune to Release Second Quarter Financial Results on August 6
9. InterMune to Present at Goldman Sachs Healthcare Conference
10. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
11. InterMune to Release First Quarter Financial Results on April 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)...  Johnson & Johnson Innovation LLC today announced the ... (JLABS @SSF), a 30,000-square foot incubator located at ... Calif. The Johnson & Johnson Innovation, JLABS ... across the healthcare spectrum including biotech, pharmaceutical, medical device, ... resident startups have been selected, including the winners of ...
(Date:3/3/2015)... , March 3, 2015 DNA Diagnostics Center ... in the world, celebrates its 20 th anniversary ... , DDC is a consumer services company that focuses ... employs over 200 associates and generates a significant portion ... over 120 countries. Peter Vitulli ...
(Date:3/3/2015)... MINNEAPOLIS, MN , March 3, 2015 /PRNewswire/ - ... biotechnology company producing sustainable chemicals, today announced it has ... acid plant located in Sarnia, Ontario ... expected to take approximately five months, with the facility ... expects construction to be completed in two months and ...
(Date:3/3/2015)... GlobalStemCellsGroup.com has recruited Mario Camacho Alcocer ... researcher and founding partner of Criogenix SA de CV ... professors who will teach the “Diplomat in Cell Therapy ... is a private company registered in the National Record ... (RENIECYT). , Camacho Alcocer will teach two-day, interactive training ...
Breaking Biology Technology:Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 2DNA Diagnostics Center, One of The World's Largest DNA Testing Labs, Celebrates Their 20th Anniversary 3BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3
... 3-V Biosciences, Inc. announced today the appointment of ... (Logo:   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) "We are ... of the 3-V senior management team," said Merdad V. ... experience in drug discovery and development, as well as ...
... fifteen minutes to analyze a sample suspected of contamination ... technology amplifies any anthrax DNA present in the sample ... cells of the deadly bacteria Bacillus anthracis. B. ... microbe that might be used intentionally to infect victims ...
... long associated with diarrhea and intestinal function may provide ... Hyperactivity Disorder) other neuropsychiatric disorders, according to a team ... Aug. 11 in Science . ... intestinal membrane receptor protein, guanylyl cyclase-C (GC-C) for its ...
Cached Biology Technology:3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer 2Nano detector for deadly anthrax 2Intestinal protein may have role in ADHD, other neurological disorders 2
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... an electromagnetic marker that predicts a patient,s response ... "Such biomarkers that identify who will benefit from ... trial-and-error prescribing and speed delivery of care for ... Zarate, M.D., of the National Institute of Mental ...
... cells facing potentially lethal antiestrogen therapy recycle to survive, ... cells have receptors for the hormone estrogen, which acts ... typically get an antiestrogen such as tamoxifen for five ... Dr. Patricia V. Schoenlein, cancer researcher in the Medical ...
... 1 OCTOBER 2008 Not only are more than ... Brown Convention Center, beginning this weekend, to participate in ... but they are bringing focus to issues of local ... theme of "Celebrating the International Year of Planet Earth," ...
Cached Biology News:Millisecond brain signals predict response to fast-acting antidepressant 2Breast cancer cells recycle to escape death by hormonal therapy 2Breast cancer cells recycle to escape death by hormonal therapy 3Earth scientists keep an eye on Texas 2Earth scientists keep an eye on Texas 3Earth scientists keep an eye on Texas 4Earth scientists keep an eye on Texas 5
... (ARCA) is a modified cap analog in ... m7G) is replaced with OCH3. Because of ... initiate transcription with the remaining hydroxyl group ... orientation. As a result, unlike transcripts synthesized ...
... structure called a ?cap? is present ... eukaryotic mRNAs and many viral RNAs. ... portion of the GTP present in ... in the synthesis of transcripts with ...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
... modified nucleotide structure called a ?cap? ... most naturally-occurring eukaryotic mRNAs and many ... for a portion of the GTP ... reaction results in the synthesis of ...
Biology Products: